- Home
- SKY vs BCTXW Comparison
SKY vs BCTXW Comparison
Compare SKY & BCTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKY
- BCTXW
- Stock Information
- Founded
- SKY 2010
- BCTXW N/A
- Country
- SKY United States
- BCTXW Canada
- Employees
- SKY N/A
- BCTXW 12
- Industry
- SKY Homebuilding
- BCTXW Biotechnology: Pharmaceutical Preparations
- Sector
- SKY Consumer Discretionary
- BCTXW Health Care
- Exchange
- SKY Nasdaq
- BCTXW Nasdaq
- Market Cap
- SKY N/A
- BCTXW N/A
- IPO Year
- SKY N/A
- BCTXW N/A
- Fundamental
- Price
- SKY $90.61
- BCTXW $0.15
- Analyst Decision
- SKY Hold
- BCTXW
- Analyst Count
- SKY 5
- BCTXW 0
- Target Price
- SKY $85.40
- BCTXW N/A
- AVG Volume (30 Days)
- SKY 1.3M
- BCTXW N/A
- Earning Date
- SKY 02-04-2025
- BCTXW N/A
- Dividend Yield
- SKY N/A
- BCTXW N/A
- EPS Growth
- SKY N/A
- BCTXW N/A
- EPS
- SKY 2.58
- BCTXW N/A
- Revenue
- SKY $2,340,474,000.00
- BCTXW N/A
- Revenue This Year
- SKY $20.55
- BCTXW N/A
- Revenue Next Year
- SKY $7.01
- BCTXW N/A
- P/E Ratio
- SKY $35.07
- BCTXW N/A
- Revenue Growth
- SKY 16.86
- BCTXW N/A
- 52 Week Low
- SKY $64.82
- BCTXW N/A
- 52 Week High
- SKY $116.49
- BCTXW N/A
- Technical
- Relative Strength Index (RSI)
- SKY 45.85
- BCTXW N/A
- Support Level
- SKY $85.25
- BCTXW N/A
- Resistance Level
- SKY $95.26
- BCTXW N/A
- Average True Range (ATR)
- SKY 3.03
- BCTXW 0.00
- MACD
- SKY 0.62
- BCTXW 0.00
- Stochastic Oscillator
- SKY 58.81
- BCTXW 0.00
About BCTXW BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.